
    
      To assess the efficacy (response rate, complete and partial) of PF-03446962 given by IV
      infusion Day 1 of a 2 week cycle (14 days = 1 cycle) in patients with advanced malignant
      pleural mesothelioma and previously treated with cytotoxic therapy.

      To assess the toxicity, safety and tolerability of PF-03446962.

      To assess the duration of response or stable disease, stable disease rate, progression-free,
      median and overall survival rates.

      To collect tissue and blood for banking and correlative science evaluation.
    
  